ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+23.97%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$71.6M
AUM Growth
+$71.6M
(-17%)
Cap. Flow
-$32.6M
Cap. Flow
% of AUM
-45.45%
Top 10 Holdings %
Top 10 Hldgs %
72.06%
Holding
37
New
3
Increased
6
Reduced
14
Closed
9
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$2.62M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$1.77M |
| 3 |
Taysha Gene Therapies
TSHA
|
$1.12M |
| 4 |
Akero Therapeutics
AKRO
|
$1.06M |
| 5 |
Terns Pharmaceuticals
TERN
|
$516K |
Top Sells
| 1 |
Unicycive Therapeutics
UNCY
|
$10.9M |
| 2 |
Insmed
INSM
|
$6.94M |
| 3 |
Enliven Therapeutics
ELVN
|
$5.22M |
| 4 |
Tourmaline Bio
TRML
|
$2.29M |
| 5 |
Merck
MRK
|
$2.06M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $9.42M | 13.15% | 1,014,940 -204,784 | -17% | -$1.9M |
|
|
2
Cidara Therapeutics
CDTX
$1.66B
| $8.75M | 12.21% | 179,569 +53,861 | +43% | +$2.62M |
|
|
WHWK
3
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $6.38M | 8.9% | 3,410,402 | – | – |
|
4
Soleno Therapeutics
SLNO
$3.6B
| $5.31M | 7.42% | 63,436 -3,700 | -6% | -$310K |
|
|
5
Tourmaline Bio
TRML
$601M
| $4.54M | 6.33% | 283,682 -143,200 | -34% | -$2.29M |
|
6
Ascendis Pharma
ASND
$11.8B
| $3.9M | 5.44% | 22,576 -764 | -3% | -$132K |
|
|
7
Insmed
INSM
$28.8B
| $3.73M | 5.21% | 37,070 -69,004 | -65% | -$6.94M |
|
8
argenx
ARGX
$43.6B
| $3.69M | 5.16% | 6,702 -321 | -5% | -$177K |
|
9
Praxis Precision Medicines
PRAX
$958M
| $3.12M | 4.35% | 74,087 -13,054 | -15% | -$549K |
|
|
10
Jazz Pharmaceuticals
JAZZ
$7.75B
| $2.79M | 3.89% | 26,283 +16,708 | +174% | +$1.77M |
|
11
Trevi Therapeutics
TRVI
$883M
| $2.7M | 3.77% | 493,735 -292,226 | -37% | -$1.6M |
|
12
Oculis Holding
OCS
$844M
| $2.07M | 2.89% | 106,718 -18,282 | -15% | -$355K |
|
13
Revolution Medicines
RVMD
$7.1B
| $2.05M | 2.86% | 55,693 -10,969 | -16% | -$404K |
|
|
BBOT
14
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $1.99M | 2.78% | 187,257 | – | – |
|
|
15
Terns Pharmaceuticals
TERN
$609M
| $1.73M | 2.42% | 463,864 +138,314 | +42% | +$516K |
|
16
Surrozen
SRZN
$104M
| $1.52M | 2.12% | 170,000 | – | – |
|
|
DRUG
17
Bright Minds Biosciences
DRUG
$276M
| $1.27M | 1.77% | 48,474 -11,274 | -19% | -$294K |
|
|
18
Taysha Gene Therapies
TSHA
$797M
| $1.12M | 1.57% | +485,669 | New | +$1.12M |
|
|
19
Akero Therapeutics
AKRO
$3.74B
| $1.06M | 1.47% | +19,772 | New | +$1.06M |
|
20
Zymeworks
ZYME
$1.12B
| $1.05M | 1.47% | 83,655 +15,196 | +22% | +$191K |
|
21
Liquidia Corp
LQDA
$2.38B
| $945K | 1.32% | 75,876 -77,606 | -51% | -$967K |
|
22
Ultragenyx Pharmaceutical
RARE
$2.89B
| $866K | 1.21% | 23,814 +2,524 | +12% | +$91.8K |
|
23
Verastem
VSTM
$569M
| $624K | 0.87% | 150,414 -25,586 | -15% | -$106K |
|
24
Fulcrum Therapeutics
FULC
$351M
| $410K | 0.57% | +59,650 | New | +$410K |
|
|
25
Unicycive Therapeutics
UNCY
$74M
| $300K | 0.42% | 62,899 -2,289,988 | -97% | -$10.9M |
|